title: The association of bone mineral density with HIV infection and antiretroviral treatment in women.
abstract: BACKGROUND
  Low bone mineral density (BMD) has been reported in HIV-infected women and men.
  
  
  METHODS
  We analysed cross-sectional BMD measured by regional dual X-ray absorptiometry at the lumbar spine (LS) and femoral neck (FN) in 152 HIV-negative and 274 HIV-positive (HIV+) women, adjusted for traditional low BMD risk factors.
  
  
  RESULTS
  BMD was significantly lower in protease inhibitor (PI) users than in all other groups, and highest in HIV-negative women. In multivariate analyses the prevalence of T-score < -1.0 was significantly higher in the HIV+ women naive to antiretroviral therapy (ART; odds ratio [OR] 4.36, 95% confidence interval [CI] 1.61, 11.8) and the women receiving PI-containing HAART (OR 3.72, CI 1.43, 9.68), with a non-significant difference in non-PI HAART users (OR 2.43, CI 0.92, 6.45), compared with HIV-negative women. In pair-wise adjusted comparisons, BMD was lower in ART-naive than in HIV-negative women (1.22 versus 1.30 g/cm2 at LS; P = 0.004), in PI compared with non-PI HAART users (1.00 versus 1.05 g/cm2 at FN; P = 0.014) and with those ART-naive (1.00 versus 1.03 g/cm2 at FN; P = 0.146). Potential confounders, including duration of ART, prior treatment regimens and traditional risk factors for low BMD did not explain these differences. Longer lopinavir use was significantly correlated with lower BMD (r2 = -0.39, P = 0.024 and r2 = -0.46, P = 0.006 at LS and FN, respectively) and longer efavirenz use with higher BMD (r2 = +0.32, P = 0.004 at FN).
  
  
  CONCLUSIONS
  HIV infection was associated with lower BMD in women, independent of the traditional risk factors for low BMD. PI-containing HAART compared with non-PI-containing HAART, and longer lopinavir use, were both associated with lower BMD, and efavirenz use was associated with higher BMD.
authors.affiliation: Montefiore Medical Centre, Bronx, NY, USA. kanastos@verizon.net
authors.forename: Kathryn
authors.initials: K
authors.lastname: Anastos
authors.forename: Dalian
authors.initials: D
authors.lastname: Lu
authors.forename: Oiuhu
authors.initials: O
authors.lastname: Shi
authors.forename: Kathleen
authors.initials: K
authors.lastname: Mulligan
authors.forename: Phyllis C
authors.initials: PC
authors.lastname: Tien
authors.forename: Ruth
authors.initials: R
authors.lastname: Freeman
authors.forename: Mardge H
authors.initials: MH
authors.lastname: Cohen
authors.forename: Jessica
authors.initials: J
authors.lastname: Justman
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Hessol
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015519:Bone Density / Q000187:drug effects*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology; D015497:HIV-1; D006801:Humans; D012307:Risk Factors
chemical_list: D019380:Anti-HIV Agents